TRIO-TECH INTERNATIONAL (TRT) Fundamental Analysis & Valuation

NYSEARCA:TRT • US8967122057

Current stock price

7.73 USD
+0.68 (+9.65%)
Last:

This TRT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TRT Profitability Analysis

1.1 Basic Checks

  • TRT had negative earnings in the past year.
  • In the past year TRT had a positive cash flow from operations.
  • In multiple years TRT reported negative net income over the last 5 years.
  • In the past 5 years TRT always reported a positive cash flow from operatings.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M 4M 6M 8M

1.2 Ratios

  • TRT has a Return On Assets of -0.24%. This is comparable to the rest of the industry: TRT outperforms 48.70% of its industry peers.
  • TRT has a Return On Equity of -0.33%. This is comparable to the rest of the industry: TRT outperforms 48.70% of its industry peers.
  • TRT's Return On Invested Capital of 0.49% is in line compared to the rest of the industry. TRT outperforms 48.70% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for TRT is significantly below the industry average of 10.89%.
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROIC 0.49%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • TRT has a Operating Margin (0.43%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of TRT has declined.
  • Looking at the Gross Margin, with a value of 19.68%, TRT is doing worse than 77.39% of the companies in the same industry.
  • TRT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.43%
PM (TTM) N/A
GM 19.68%
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

5

2. TRT Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TRT is destroying value.
  • The number of shares outstanding for TRT has been increased compared to 1 year ago.
  • The number of shares outstanding for TRT has been increased compared to 5 years ago.
  • Compared to 1 year ago, TRT has an improved debt to assets ratio.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • TRT has an Altman-Z score of 5.06. This indicates that TRT is financially healthy and has little risk of bankruptcy at the moment.
  • TRT has a Altman-Z score of 5.06. This is comparable to the rest of the industry: TRT outperforms 51.30% of its industry peers.
  • The Debt to FCF ratio of TRT is 7.26, which is on the high side as it means it would take TRT, 7.26 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 7.26, TRT perfoms like the industry average, outperforming 48.70% of the companies in the same industry.
  • TRT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.02, TRT is doing good in the industry, outperforming 66.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Altman-Z 5.06
ROIC/WACC0.04
WACC11.98%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • TRT has a Current Ratio of 2.96. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TRT (2.96) is comparable to the rest of the industry.
  • TRT has a Quick Ratio of 2.72. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TRT (2.72) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.72
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2

3. TRT Growth Analysis

3.1 Past

  • TRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.03%.
  • Looking at the last year, TRT shows a very strong growth in Revenue. The Revenue has grown by 27.63%.
  • TRT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.14% yearly.
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

1

4. TRT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 86.09% of the companies in the same industry are more expensive than TRT, based on the Enterprise Value to EBITDA ratio.
  • TRT's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 493.71
EV/EBITDA 16.68
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. TRT Dividend Analysis

5.1 Amount

  • TRT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

TRT Fundamentals: All Metrics, Ratios and Statistics

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (4/22/2026, 2:28:06 PM)

7.73

+0.68 (+9.65%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)02-13
Earnings (Next)05-11
Inst Owners22.53%
Inst Owner Change5.35%
Ins Owners27.02%
Ins Owner Change3.35%
Market Cap67.64M
Revenue(TTM)49.22M
Net Income(TTM)-109.00K
Analysts0
Price TargetN/A
Short Float %0.22%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.37
P/FCF 493.71
P/OCF 57.13
P/B 2.02
P/tB 2.02
EV/EBITDA 16.68
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.02
FCFY0.2%
OCF(TTM)0.14
OCFY1.75%
SpS5.62
BVpS3.83
TBVpS3.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.24%
ROE -0.33%
ROCE 0.62%
ROIC 0.49%
ROICexc 0.93%
ROICexgc 0.93%
OM 0.43%
PM (TTM) N/A
GM 19.68%
FCFM 0.28%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
ROICexc(3y)5.18%
ROICexc(5y)N/A
ROICexgc(3y)5.18%
ROICexgc(5y)N/A
ROCE(3y)3.55%
ROCE(5y)N/A
ROICexgc growth 3Y-59.08%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.08%
ROICexc growth 5YN/A
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 7.26
Debt/EBITDA 0.28
Cap/Depr 45.68%
Cap/Sales 2.13%
Interest Coverage 3.37
Cash Conversion 47.28%
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.72
Altman-Z 5.06
F-Score4
WACC11.98%
ROIC/WACC0.04
Cap/Depr(3y)45.5%
Cap/Depr(5y)44.1%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.63%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%81.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.27%
EBIT growth 3Y-59.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-97.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.88%
OCF growth 3Y-44.07%
OCF growth 5Y-34.21%

TRIO-TECH INTERNATIONAL / TRT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRIO-TECH INTERNATIONAL?

ChartMill assigns a fundamental rating of 3 / 10 to TRT.


Can you provide the valuation status for TRIO-TECH INTERNATIONAL?

ChartMill assigns a valuation rating of 1 / 10 to TRIO-TECH INTERNATIONAL (TRT). This can be considered as Overvalued.


How profitable is TRIO-TECH INTERNATIONAL (TRT) stock?

TRIO-TECH INTERNATIONAL (TRT) has a profitability rating of 3 / 10.